Stock Watch: The Pandemic Cannot Mask Roche’s Weaknesses
Declining COVID-19 Sales, Biosimilar Exposure And Pipeline Failures Bite
Executive Summary
Declining COVID-19-related diagnostic and therapeutic sales are likely to expose long-standing weaknesses and amplify the effects of new pressures that were masked during the pandemic.
You may also be interested in...
Novartis’s Kesimpta Already A Big Earner But Leqvio Is Slow Burner
Novartis’s multiple sclerosis treatment Kesimpta has shot out of the gates and bidding fair to contribute generously to the firm’s coffers, while new cholesterol drug Leqvio struggles, Q1 results show.
Roche's SERD Setback Means Menarini Retains An Edge
Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.
Stock Watch: Second-Order Pandemic Effects In J&J’s First Quarter
The second-order pandemic effects on labor and logistics that have plagued other sectors appeared across J&J’s earnings announcement. With the biggest impact at its consumer business, why then has demand for J&J’s COVID-19 vaccine plummeted?